Carvykti denied for failing step therapy by Aetna?

Aetna's specific coverage criteria for carvykti are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Applies Step Therapy to Carvykti — and Why You Can Appeal

Carvykti (ciltacabtagene autoleucel) is a CAR-T cell therapy approved for relapsed or refractory multiple myeloma after prior lines of therapy. A step-therapy denial from Aetna means the plan contends that certain earlier treatments have not yet been tried or documented as having failed. Given the nature of multiple myeloma, where patients have often exhausted several regimens before reaching CAR-T eligibility, this denial is frequently based on incomplete documentation rather than a genuine gap in treatment history.

## Why This Is Appealable

Step-therapy requirements must track the FDA-approved prescribing information and Aetna's published clinical policy — they cannot impose prerequisites that go beyond those sources. If your chart shows you have already received the required prior lines of therapy, the denial rests on a documentation gap that can be closed on appeal. Many states also have step-therapy override laws that allow a prescriber to demonstrate that prior-step therapy is contraindicated, was tried and failed, or is otherwise clinically inappropriate.

## Federal Appeal Framework

• Internal appeal: File within the deadline on your denial letter. Under ERISA §503, Aetna must provide a full-and-fair review of all submitted evidence.
• External review: Under ACA §2719, an independent IRO can overturn a step-therapy denial if the clinical record supports override. The general external-review window is approximately four months from the original denial — confirm the exact date on your denial letter.
• Expedited review: Available when the standard timeline would seriously jeopardize health or the ability to regain maximum function; request it in writing simultaneously with the internal appeal.
• State law override: If this is a fully insured plan, check whether your state's step-therapy override statute applies; it may provide an independent, faster pathway.

## Documentation to Gather

1. Complete prior-therapy history — a chronological, outcome-annotated list of every prior line of therapy, including start/stop dates, doses (per the treatment record), and documented response or failure reason. 2. Diagnosis and staging records — bone marrow biopsy, cytogenetics, and staging documents confirming the indication. 3. Treating oncologist's letter — must map the patient's prior treatment history to the specific step requirements in Aetna's published policy and the FDA label, and explain why Carvykti is medically necessary now. 4. Institutional treatment summary — from the CAR-T center, confirming eligibility assessment and leukapheresis scheduling if already initiated.

## Criteria-Mapping Structure

Download Aetna's current clinical policy bulletin for Carvykti. Extract each step-therapy prerequisite verbatim. Build a two-column table: left column is the policy requirement; right column is the specific chart entry (date, regimen name, outcome note) that satisfies it. An unanswered row signals a documentation gap — work with the prescriber to fill it before submitting.

## Next Step

If any prior line of therapy appears missing from the administrative record, obtain and attach the treatment summaries from every facility where those lines were administered. A complete chronological oncology record is the fastest path to overturn.